TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) Files An 8-K Regulation FD Disclosure
Item 7.01
| Regulation FD Disclosure. |
Tonix Pharmaceuticals Holding Corp. (the Company) intends to an
updated investor presentation to conduct meetings with investors,
stockholders and analysts and at investor conferences, and which
the Company intends to place on its website, which may contain
non-public information.A copy of the presentation is filed as
Exhibit 99.01.
The information contained in Item 7.01 of this Current Report on
Form 8-K, including Exhibit 99.01, is furnished to, and shall not
be deemed to be filed for the purposes of, Section 18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject
to the liabilities of that section.The information contained in
Item 7.01 of this Current Report shall not be incorporated by
reference into any registration statement or any other document
filed to the Securities Act of 1933, as amended, except as
otherwise expressly stated in such filing.By filing this Current
Report on Form 8-K and furnishing the information contained in
this Item 7.01, including Exhibit 99.01, the Company makes no
admission as to the materiality of any such information that it
is furnishing.
| Item 9.01 | Financial Statements and Exhibits. |
(d)Exhibits.
| 99.01 | Corporate Presentation by the Company for April 2017* |
______
* Furnished herewith.
TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) Recent Trading Information
TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) closed its last trading session up +0.23 at 4.09 with 869,454 shares trading hands.
